Prelude Therapeutics Inc

Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.

PRLD | NDAQ

Overview

Corporate Details

ISIN(s):: US74065P1012
LEI:
Country:: United States of America
Address:: 175 INNOVATION BOULEVARD, 19805 WILMINGTON
Website:: https://preludetx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet medical needs. The company's pipeline features multiple novel drug candidates, including first-in-class, highly selective SMARCA2 and KAT6A protein degraders. Leveraging its expertise in targeted protein degradation, Prelude Therapeutics also develops next-generation degrader antibody conjugates (ADCs) through partnerships. The company employs a science-driven, target-agnostic approach to create therapies that precisely address the drivers of cancer cell growth and mechanisms of resistance, aiming to advance transformational treatments into clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prelude Therapeutics Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prelude Therapeutics Inc

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Prelude Therapeutics Inc via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
Abpro Holdings, Inc. Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.	United States of America	ABP
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
ACADIA PHARMACEUTICALS INC Develops and commercializes innovative therapies for CNS disorders and rare diseases.	United States of America	ACAD
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
ACHIEVE LIFE SCIENCES, INC. Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.	United States of America	ACHV
AC Immune SA Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.	United States of America	ACIU
Aclaris Therapeutics, Inc. A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.	United States of America	ACRS
Actinium Pharmaceuticals, Inc. Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.	United States of America	ATNM